Australia markets open in 9 hours 32 minutes

Fate Therapeutics, Inc. (FATE)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
5.39+0.16 (+3.06%)
At close: 04:00PM EDT
5.40 +0.01 (+0.19%)
After hours: 05:50PM EDT

Fate Therapeutics, Inc.

12278 Scripps Summit Drive
San Diego, CA 92131
United States
858 875 1800

Full-time employees551

Key executives

NameTitlePayExercisedYear born
Mr. J. Scott WolchkoFounder, CEO, Pres & Director976k25.12M1970
Mr. Edward J. Dulac IIIChief Financial Officer588k821.37k1976
Ms. Cindy R. TahlGen. Counsel & Corp. Sec.602k13.37M1973
Dr. Bahram Valamehr Ph.D.Chief R&D Officer602k7.11M1977
Dr. Yu-Waye Chu M.D.Chief Medical Officer602k263.51kN/A
Mr. Jim Beitel M.B.A.Sr. VP of Corp. Devel.N/AN/AN/A
Dr. Sarah CooleySr. VP of Clinical TranslationN/AN/AN/A
Dr. Jerome Bressi Ph.D.Sr. VP of Regulatory & QualityN/AN/AN/A
Mr. Brian T. Powl M.B.A., M.S.Chief Commercial OfficerN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Corporate governance

Fate Therapeutics, Inc.’s ISS governance QualityScore as of 1 March 2023 is 7. The pillar scores are Audit: 7; Board: 6; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.